SSSara Suhl

Sara Suhl

*This is an algorithmically generated author record based on publicly available information.

Sara Suhl has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An Update on Single-Cell RNA Sequencing in Illuminating Disease Mechanisms of Cutaneous T-Cell Lymphoma

    by Sara Suhl, Alexander Kaminsky, Caroline Chen, Brigit A. Lapolla, Maggie H. Zhou, Joshua Kent, Abigail Marx, Ikenna David Nebo, Geat Ramush, Sophia Luyten, et al.

    Cutaneous T-cell Lymphomas (CTCLs) are a heterogeneous group of non-Hodgkin lymphomas that currently have an incompletely understood pathophysiology and several challenges in both diagnosis and management. Single-cell RNA sequencing (scRNA-seq) is a powerful tool that enables the analysis of gene expression at the individual-cell level, revealing cellular heterogeneity and a complex tumor microenvironment. As single-cell RNA sequencing has become increasingly utilized, we aimed to provide an update on recent notable applications of single-cell RNA sequencing in CTCL and their findings. The included studies highlight the intricate network of interactions in the tumor microenvironment that contributes to tumorigenesis. While CTCL is notoriously heterogeneous, our results identify key markers that prove promising for diagnosis, prognostication, and therapeutic targets.


  • Renal Evaluation and Protection

    by Rawan Amir, Sara Suhl, Charles M. Alexander


  • 676-P: Ideal Ketone Test Training among Type 1 Patients in Context of Risk Associated with SGLT2 Inhibitors

    by Jonathan B. Rost, Sara Suhl, Keaton C. Stoner, Caterina Florissi, Rebecca Gowen, Richard Wood

    SGLT2 inhibitors are not approved for people with type 1 diabetes in the U.S. due to elevated risk of diabetic ketoacidosis (DKA), prompting interest in ketone testing education. This study surveyed 4,612 people with type 1 diabetes across the U.S., EU, and Canada regarding their preferred method and duration of ketone testing education if they were to start a new therapy that increased DKA risk. Overall, a phone app was the preferred method of education, with some country-level differences apparent. In the U.S., Germany, and the Netherlands, 15-30 minutes was the most selected training time duration, while the remaining countries most commonly selected 1-2 hours. When considering the safety of SGLT2 therapy for type 1 patients, this data lends important insights into the feasibility and optimal composition of ketone test training. Disclosure: J.B. Rost: Employee; Self; This work was funded by dQ&A Diabetes Research, a provider of research services to multiple companies and patient organizations in the diabetes field. S. Suhl: Employee; Self; This work was funded by dQ&A Diabetes Research, a provider of research services to multiple companies and patient organizations in the diabetes field. K.C. Stoner: Other Relationship; Self; Various companies and organizations. C. Florissi: Employee; Self; This work was funded by dQ&A Diabetes Research, a provider of research services to multiple companies and patient organizations in the diabetes field. R. Gowen: Employee; Self; This work was funded by dQ&A Diabetes Research, a provider of research services to multiple companies and patient organizations in the diabetes field. R. Wood: Consultant; Self; Abbott, ADOCIA, American Diabetes Association, Ascensia Diabetes Care, Boehringer Ingelheim Pharmaceuticals, Inc., CeQur Corporation, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation. Employee; Self; dQ&A Market Research Inc.

  • 737-P: Positive Impact of Social Support and Diabetes Community Participation on Patient-Reported Outcomes

    by Sara Suhl, Jonathan B. Rost, Keaton C. Stoner, Rebecca Gowen, Caterina Florissi, Richard Wood

    Social support plays an important role in both mental and physical well-being. This study used patient-reported outcomes to better understand the effect of social support and diabetes communities on the behaviors and health outcomes of those living with diabetes. People with diabetes (n=4,717) from an opted-in U.S. research panel were surveyed about their level of social support using the Interpersonal Support Evaluation List-12 (ISEL-12). Physical activity level was determined using the International Physical Activity Questionnaire Short Form (IPAQ-SF) and health and demographic information were collected. Findings show that higher levels of support are associated with better glycemic control, healthier lifestyle choices, and lower rates of diabetes complications and comorbidities. Notably, when controlling for overall level of social support and evaluating participants within one SD of the ISEL-12 mean, diabetes community members are more likely than those not in a community to have high diet adherence (≥80%) and high levels of physical activity. These diabetes community members are also less likely to have A1c >7, heart/circulation problems, high blood pressure, and cholesterol/triglyceride problems. These findings emphasize the importance of social support on the overall health of those with diabetes and suggest that diabetes communities are an important tool for managing diabetes. Disclosure: S. Suhl: Employee; Self; This work was funded by dQ&A Diabetes Research, a provider of research services to multiple companies and patient organizations in the diabetes field. J.B. Rost: Employee; Self; This work was funded by dQ&A Diabetes Research, a provider of research services to multiple companies and patient organizations in the diabetes field. K.C. Stoner: Other Relationship; Self; Various companies and organizations. R. Gowen: Employee; Self; This work was funded by dQ&A Diabetes Research, a provider of research services to multiple companies and patient organizations in the diabetes field. C. Florissi: Employee; Self; This work was funded by dQ&A Diabetes Research, a provider of research services to multiple companies and patient organizations in the diabetes field. R. Wood: Consultant; Self; Abbott, ADOCIA, American Diabetes Association, Ascensia Diabetes Care, Boehringer Ingelheim Pharmaceuticals, Inc., CeQur Corporation, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation. Employee; Self; dQ&A Market Research Inc.